LX-7101

Investigational

Details

Stereochemistry	ACHIRAL
Molecular Formula	C23H29N7O3
Molecular Weight	451.5215
Optical Activity	NONE
Defined Stereocenters	0 / 0
E/Z Centers	0
Charge	0

SHOW SMILES / InChI

Structure Search

SMILES

CN(C)C(=O)OC1=CC(NC(=O)C2(CN)CCN(CC2)C3=NC=NC4=C3C(C)=CN4)=CC=C1

InChI

InChIKey=PWPNYABQEOGNNC-UHFFFAOYSA-N

InChI=1S/C23H29N7O3/c1-15-12-25-19-18(15)20(27-14-26-19)30-9-7-23(13-24,8-10-30)21(31)28-16-5-4-6-17(11-16)33-22(32)29(2)3/h4-6,11-12,14H,7-10,13,24H2,1-3H3,(H,28,31)(H,25,26,27)

HIDE SMILES / InChI

Description
Sources: https://www.ncbi.nlm.nih.gov/pubmed/26233434
Curator's Comment: description was created based on several sources, including https://www.ncbi.nlm.nih.gov/pubmed/25589936

LX-7101 (Lexicon Pharmaceuticals) was advanced to Phase-I clinical trials for treatment open-angle glaucoma or ocular hypertension. This drug is a potent inhibitor of LIM-kinase 2 (LIMK2) kinase and inhibits to less extent LIMK1 and Rho-associated protein kinase 2 (ROCK2).

Originator

Approval Year

Targets

Primary Target	Pharmacology	Potency
LIM domain kinase 2 3 Target ID: CHEMBL5932 Sources: https://www.ncbi.nlm.nih.gov/pubmed/25589936	Inhibitor 8297	4.3 nM [IC50]
LIM domain kinase 1 3 Target ID: CHEMBL3836 Sources: https://www.ncbi.nlm.nih.gov/pubmed/25589936	Inhibitor 8297	32.0 nM [IC50]
Rho-associated protein kinase 2 25 Target ID: CHEMBL2973 Sources: https://www.ncbi.nlm.nih.gov/pubmed/25589936	Inhibitor 8297	32.0 nM [IC50]

Conditions

Condition	Modality	Targets	Highest Phase	Product
Open-angle glaucoma 51 Sources: https://clinicaltrials.gov/ct2/show/NCT01528111	Primary		Phase I 428	Unknown Approved Use Unknown
Ocular hypertension 50 Sources: https://clinicaltrials.gov/ct2/show/NCT01528111	Primary		Phase I 428	Unknown Approved Use Unknown

Sourcing

Vendor/Aggregator	ID	URL
1PlusChem LLC	1P008U31	https://www.1pchem.com/search?query=1P008U31
AChemBlock	M15681	http://www.achemblock.com/catalogsearch/result/?q=M15681
ApexBio Technology	B5863	https://www.apexbt.com/catalogsearch/result/?q=B5863
AstaTech	C14316	http://astatechinc.com/CPSResult.php?CRNO=C14316
BLD Pharm	BD629971	http://www.bldpharm.com/search/Search.html?keyword=BD629971
Cayman Chemical	21209	http://www.caymanchem.com/app/template/Product.vm/catalog/21209
Chem Scene	CS-5103	http://www.chemscene.com/goproductList/searchProductList?productObj=CS-5103
Excenen	EX-A2288	http://www.excenen.com/searchresultlist.php?id=EX-A2288
MedChem Express	HY-12659	https://www.medchemexpress.com/search.html?q=HY-12659&ft=&fa=&fp=
MolPort	MolPort-044-561-838	https://www.molport.com/shop/molecule-link/MolPort-044-561-838
MolPort	MolPort-046-416-915	https://www.molport.com/shop/molecule-link/MolPort-046-416-915
Molnova	M10664	https://www.molnova.com/en/serch-list.html?keywords=M10664
MuseChem	I000697	https://www.musechem.com/product/I000697.html
MuseChem	R066798	https://www.musechem.com/product/R066798.html
ShangHai Biochempartner	BCP000294	http://www.biochempartner.com/search_BCP000294
ShangHai Biochempartner	BCP02298	http://www.biochempartner.com/search_BCP02298
eMolecules	72973106	https://orderbb.emolecules.com/search/#?query=72973106
eMolecules	93437748	https://orderbb.emolecules.com/search/#?query=93437748
mcule	MCULE-8096869004	https://mcule.com/MCULE-8096869004/

PubMed

Title	Date	PubMed
Discovery and Development of LX7101, a Dual LIM-Kinase and ROCK Inhibitor for the Treatment of Glaucoma.	2015 Jan 8	25589936
Design, synthesis and biological characterization of selective LIMK inhibitors.	2015 Sep 15	26233434

Patents

Sample Use Guides

In Vivo Use Guide

Low dose LX7101: Days 1-3: once daily dose in study eye (eye with highest IOP); Days 4-7: once daily dose in study eye (eye with highest IOP) and fellow eye (other eye); Days 8-14: twice daily dose in study eye (eye with highest IOP) and fellow eye High dose LX7101: Days 1-3: once daily dose in study eye (eye with highest IOP); Days 4-7: once daily dose in study eye (eye with highest IOP) and fellow eye (other eye); Days 8-14: twice daily dose in study eye (eye with highest IOP) and fellow eye (other eye).

Route of Administration: Other

In Vitro Use Guide

In vitro assay was used to identify LIMK and ROCK inhibitors. For kinetic studies, the final LX7101concentrations varied from 0 to 100 nM.

Name

Type

Language

LX-7101

Code

English

LX7101

Code

English

CARBAMIC ACID, N,N-DIMETHYL-, 3-(((4-(AMINOMETHYL)-1-(5-METHYL-7H-PYRROLO(2,3-D)PYRIMIDIN-4-YL)-4-PIPERIDINYL)CARBONYL)AMINO)PHENYL ESTER

Systematic Name

English

Code System Code Type Description

PUBCHEM

56962369

Created by admin on Sat Dec 16 02:15:31 GMT 2023 , Edited by admin on Sat Dec 16 02:15:31 GMT 2023

PRIMARY

FDA UNII

74B3C4ZT96

Created by admin on Sat Dec 16 02:15:31 GMT 2023 , Edited by admin on Sat Dec 16 02:15:31 GMT 2023

PRIMARY

CAS

1192189-69-7

Created by admin on Sat Dec 16 02:15:31 GMT 2023 , Edited by admin on Sat Dec 16 02:15:31 GMT 2023

PRIMARY

ACTIVE MOIETY


					74B3C4ZT96

LX-7101

SALT/SOLVATE (PARENT)


					S5G8WJ39X9

LX-7101 HYDROCHLORIDE

Details

SMILES

InChI

DescriptionSources: https://www.ncbi.nlm.nih.gov/pubmed/26233434Curator's Comment: description was created based on several sources, including https://www.ncbi.nlm.nih.gov/pubmed/25589936

Originator

Approval Year

Targets

Conditions

Approved Use

Approved Use

Sourcing

PubMed

Patents

Sample Use Guides

Description
Sources: https://www.ncbi.nlm.nih.gov/pubmed/26233434
Curator's Comment: description was created based on several sources, including https://www.ncbi.nlm.nih.gov/pubmed/25589936